Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women.

MLA

Xu, Binghe, et al. “Pharmacokinetics, Safety, Activity, and Biomarker Analysis of Palbociclib plus Letrozole as First-Line Treatment for ER+/HER2- Advanced Breast Cancer in Chinese Women.” Cancer Chemotherapy & Pharmacology, vol. 88, no. 1, July 2021, pp. 131–41. EBSCOhost, https://doi.org/10.1007/s00280-021-04263-9.

APA

Xu, B., Li, H., Zhang, Q., Sun, W., Yu, Y., Li, W., Wang, S., Liao, N., Shen, P., Liu, Y., Huang, Y., Linn, C., Zhao, H., Jiang, J., & Wang, D. (2021). Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. Cancer Chemotherapy & Pharmacology, 88(1), 131–141. https://doi.org/10.1007/s00280-021-04263-9

Chicago

Xu, Binghe, Huiping Li, Qingyuan Zhang, Wan Sun, Yanke Yu, Wei Li, Shusen Wang, et al. 2021. “Pharmacokinetics, Safety, Activity, and Biomarker Analysis of Palbociclib plus Letrozole as First-Line Treatment for ER+/HER2- Advanced Breast Cancer in Chinese Women.” Cancer Chemotherapy & Pharmacology 88 (1): 131–41. doi:10.1007/s00280-021-04263-9.